IDEXX Laboratories Slashes FY22 Outlook - Update
(RTTNews) - While reporting financial results for the second quarter on Tuesday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) slashed its earnings and revenue growth guidance for the full-year 2022.
For fiscal 2022, the company now projects earnings in a range of $7.77 to $8.05 per share on revenues between $3.305 billion and $3.385 billion, with revenue growth of 3 to 5.5 percent and organic revenue growth of 5.5 to 8 percent.
Previously, the company expected earnings in a range of $8.11 to $8.35 per share on revenue growth of 5.5 to 8 percent and organic revenue growth of 7.5 to 10 percent.
On average, 11 analysts polled by Thomson Reuters expect the company to report earnings of $8.27 per share on revenues of $3.42 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
IDEXX Laboratories Slashes FY24 Outlook - Update
IDEXX Labs Launch First Veterinary Diagnostic Test To Detect Kidney Injury In Cats And Dogs
U.S. Consumer Confidence Index Edges Lower In August
U.S. Durable Goods Orders Slump 2.8% In July, Much Less Than Expected
Bay Street May Open On Weak Note
U.S. Durable Goods Orders Tumble Less Than Expected In July
FTSE 100 Modestly Lower
